Amino acids levels as a potential biomarker in myasthenia gravis

Piotr Kośliński; Łukasz Rzepiński; Marcin Koba; Marcin Gackowski; Zdzisław Maciejek

doi:10.5114/fn.2022.114053

eISSN: 1509-572x
ISSN: 1641-4640

Folia Neuropathologica

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2022
vol. 60

Send email

Copy url:

abstract:

Case report

Amino acids levels as a potential biomarker in myasthenia gravis

Piotr Kośliński

¹

,

Łukasz Rzepiński

^{2, 3}

,

Marcin Koba

¹

,

Marcin Gackowski

¹

,

Zdzisław Maciejek

^{2, 3}

Department of Toxicology and Bromatology, Faculty of Pharmacy, Collegium Medicum of Nicolaus Copernicus University, Bydgoszcz, Poland
Department of Neurology, 10th Military Research Hospital and Polyclinic, Bydgoszcz, Poland
Sanitas – Neurology Outpatient Clinic, Bydgoszcz, Poland

Folia Neuropathol 2022; 60 (1): 122-127

DOI: https://doi.org/10.5114/fn.2022.114053

Online publish date: 2022/03/04

View full text Get citation

PlumX metrics:

The search for new diagnostic and therapeutic approaches for myasthenia gravis (MG) is highly desirable. Therefore, the aim of the present study is to assess the profile of non-essential amino acids in the serum of MG patients. We evaluated the serum levels of non-essential amino acids in MG patients (n = 10) and control subjects (CS, n = 10) using high-performance liquid chromatography (HPLC) method and assuming a two-fold concentration difference between the groups as significant. Serum levels of aspartic acid and glutamic acid in MG patients were significantly higher than in CS. There were no significant differences in mean serum levels of glycine, proline, alanine, serine, cysteine, arginine and tyrosine between MG patients and CS. The results indicate the need for further research to assess the role of non-essential amino acids in MG. Moreover, our preliminary results suggest that the metabolism of some amino acids seems to be changed in patients with MG. Therefore, we conclude that amino acids profiling might be helpful in searching for putative biomarkers of the central nervous system diseases such as myasthenia gravis.

keywords:

Amino acids levels as a potential biomarker in myasthenia gravis

Piotr Kośliński 1 , Łukasz Rzepiński 2, 3 , Marcin Koba 1 , Marcin Gackowski 1 , Zdzisław Maciejek 2, 3

metabolomics, amino acid profiling, myasthenia gravis, diagnosis, biomarker

Piotr Kośliński

¹

,

Łukasz Rzepiński

^{2, 3}

,

Marcin Koba

¹

,

Marcin Gackowski

¹

,

Zdzisław Maciejek

^{2, 3}